MX336346B - Compuestos heterociclicos y su uso como inhibidores de la cinasa 3 de glucogeno sintasa. - Google Patents

Compuestos heterociclicos y su uso como inhibidores de la cinasa 3 de glucogeno sintasa.

Info

Publication number
MX336346B
MX336346B MX2013007702A MX2013007702A MX336346B MX 336346 B MX336346 B MX 336346B MX 2013007702 A MX2013007702 A MX 2013007702A MX 2013007702 A MX2013007702 A MX 2013007702A MX 336346 B MX336346 B MX 336346B
Authority
MX
Mexico
Prior art keywords
glycogen synthase
synthase kinase
treatment
heterocyclic compounds
inhibitors
Prior art date
Application number
MX2013007702A
Other languages
English (en)
Other versions
MX2013007702A (es
Inventor
Wilfried Hornberger
Margaretha Henrica Maria Bakker
Helmut Mack
Sean Colm Turner
Marcel Van Gaalen
Carolin Hoft
Original Assignee
Abbvie Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Deutschland filed Critical Abbvie Deutschland
Publication of MX2013007702A publication Critical patent/MX2013007702A/es
Publication of MX336346B publication Critical patent/MX336346B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms

Abstract

La presente invención se refiere a compuestos heterocíclicos novedosos de fórmula (I), en donde las variables son como se define en las reivindicaciones o la descripción, que son útiles para inhibir la cinasa 3 de glucógeno sintasa (GSK-3), composiciones que contienen los compuestos, su uso para preparar un medicamento para el tratamiento de un trastorno susceptible de tratamiento con un compuesto que modula, preferiblemente inhibe, la actividad de la cinasa 3ß de glucógeno sintasa, y métodos de tratamiento de trastornos susceptibles de tratamiento con un compuesto que modula la actividad de la cinasa 3í de glucógeno sintasa, usando los compuestos.
MX2013007702A 2010-12-30 2011-12-30 Compuestos heterociclicos y su uso como inhibidores de la cinasa 3 de glucogeno sintasa. MX336346B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201061428478P 2010-12-30 2010-12-30
US201161521868P 2011-08-10 2011-08-10
PCT/EP2011/074272 WO2012089828A2 (en) 2010-12-30 2011-12-30 Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors

Publications (2)

Publication Number Publication Date
MX2013007702A MX2013007702A (es) 2013-11-20
MX336346B true MX336346B (es) 2016-01-15

Family

ID=45524498

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013007702A MX336346B (es) 2010-12-30 2011-12-30 Compuestos heterociclicos y su uso como inhibidores de la cinasa 3 de glucogeno sintasa.

Country Status (15)

Country Link
US (2) US9090592B2 (es)
EP (2) EP3351543A1 (es)
JP (2) JP6144201B2 (es)
KR (1) KR101860297B1 (es)
CN (1) CN103476766B (es)
AU (1) AU2011351375B2 (es)
BR (1) BR112013016928A2 (es)
CA (1) CA2821863A1 (es)
IL (1) IL226676A (es)
MX (1) MX336346B (es)
NZ (1) NZ611314A (es)
RU (1) RU2623427C2 (es)
SG (2) SG191789A1 (es)
WO (1) WO2012089828A2 (es)
ZA (1) ZA201304756B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8642598B2 (en) * 2006-10-21 2014-02-04 Abbvie Inc. Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors
CA2810954A1 (en) 2010-09-27 2012-04-05 Abbott Gmbh & Co. Kg Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
US9090592B2 (en) * 2010-12-30 2015-07-28 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
JP6534098B2 (ja) * 2014-09-12 2019-06-26 国立大学法人 鹿児島大学 成人ｔ細胞白血病治療薬
US11248007B2 (en) * 2017-03-08 2022-02-15 Cornell University Inhibitors of MALT1 and uses thereof
RU2739489C2 (ru) * 2018-03-06 2020-12-24 Закрытое Акционерное Общество "Биокад" Новые гетероциклические соединения как ингибиторы CDK8/19
AU2019359823A1 (en) * 2018-10-17 2021-05-20 Duke University Quinone reductase 2 inhibitors for use as neuroprotective agents
US20220133740A1 (en) 2019-02-08 2022-05-05 Frequency Therapeutics, Inc. Valproic acid compounds and wnt agonists for treating ear disorders
US11753413B2 (en) 2020-06-19 2023-09-12 Incyte Corporation Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors
US11691971B2 (en) 2020-06-19 2023-07-04 Incyte Corporation Naphthyridinone compounds as JAK2 V617F inhibitors
MX2023000056A (es) 2020-07-02 2023-04-12 Incyte Corp Compuestos tricíclicos de urea como inhibidores de la variante v617f de la cinasa de janus 2 (jak2 v617f).
WO2022006456A1 (en) 2020-07-02 2022-01-06 Incyte Corporation Tricyclic pyridone compounds as jak2 v617f inhibitors
US11661422B2 (en) 2020-08-27 2023-05-30 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
WO2022140231A1 (en) 2020-12-21 2022-06-30 Incyte Corporation Deazaguaine compounds as jak2 v617f inhibitors
TW202302589A (zh) 2021-02-25 2023-01-16 美商英塞特公司 作為ｊａｋ２ ｖ６１７ｆ抑制劑之螺環內醯胺

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY115155A (en) 1993-09-09 2003-04-30 Upjohn Co Substituted oxazine and thiazine oxazolidinone antimicrobials.
DE69631347T2 (de) 1995-09-15 2004-10-07 Upjohn Co Aminoaryl oxazolidinone n-oxide
AUPP003197A0 (en) * 1997-09-03 1997-11-20 Fujisawa Pharmaceutical Co., Ltd. New heterocyclic compounds
US20030220234A1 (en) 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
JP4533534B2 (ja) 1998-06-19 2010-09-01 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド グリコーゲンシンターゼキナーゼ３のインヒビター
UA73492C2 (en) * 1999-01-19 2005-08-15 Aromatic heterocyclic compounds as antiinflammatory agents
GB9918037D0 (en) 1999-07-30 1999-09-29 Biochemie Gmbh Organic compounds
US6387900B1 (en) 1999-08-12 2002-05-14 Pharmacia & Upjohn S.P.A. 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents
GT200100147A (es) 2000-07-31 2002-06-25 Derivados de imidazol
AP2001002266A0 (en) 2000-08-31 2001-09-30 Pfizer Prod Inc Pyrazole derivatives.
CA2422371C (en) 2000-09-15 2010-05-18 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
JP2004529207A (ja) 2001-04-30 2004-09-24 ツェンタリス ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｌｈｒｈアンタゴニストの中間の用量での痴呆及び神経変性疾患の治療
DE10123586A1 (de) 2001-05-08 2002-11-28 Schering Ag 3,5-Diamino-1,2,4-triazole als Kinase Inhibitoren
EP1256578B1 (en) 2001-05-11 2006-01-11 Pfizer Products Inc. Thiazole derivatives and their use as cdk inhibitors
SE0102439D0 (sv) 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
JP5039268B2 (ja) 2001-10-26 2012-10-03 アベンティス・ファーマスーティカルズ・インコーポレイテツド ベンゾイミダゾールおよび類縁体および蛋白キナーゼ阻害剤としてのその使用
DE60236322D1 (de) 2001-12-07 2010-06-17 Vertex Pharma Verbindungen auf pyrimidin-basis als gsk-3-hemmer
SE0104340D0 (sv) 2001-12-20 2001-12-20 Astrazeneca Ab New compounds
SE0104341D0 (sv) 2001-12-20 2001-12-20 Astrazeneca Ab New use
DE60221283T2 (de) 2001-12-21 2008-03-20 Astrazeneca Ab Verwendung von oxindolderivaten zur behandlung von mit demenz in zusammenhang stehenden krankheiten, alzheimer-krankheit und mit glycogensynthasekinase-3 assoziierten leiden
TW200301123A (en) 2001-12-21 2003-07-01 Astrazeneca Uk Ltd New use
SE0200979D0 (sv) 2002-03-28 2002-03-28 Astrazeneca Ab New compounds
US7601718B2 (en) 2003-02-06 2009-10-13 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
PL2256106T3 (pl) 2003-07-22 2015-08-31 Astex Therapeutics Ltd Związki 3,4-pochodne 1h-pirazolu i ich zastosowanie jako kinazy zależne od cyklin (cdk) i modulatory kinazy syntazy glikogenu-3 (gsk-3)
CA2536253A1 (en) 2003-08-20 2005-03-03 Vertex Pharmaceuticals Incorporated Aminofurazan compounds useful as protein kinase inhibitors
WO2005061516A1 (en) 2003-12-04 2005-07-07 Smithkline Beecham Corporation Novel chemical compounds
EP1694686A1 (en) 2003-12-19 2006-08-30 Takeda San Diego, Inc. Kinase inhibitors
EP1586318A1 (en) 2004-04-05 2005-10-19 Neuropharma S.A.U. Thiadiazolidinones as GSK-3 inhibitors
DE602004009344T2 (de) 2004-04-19 2008-07-10 Symed Labs Ltd., Hyderabad Neues verfahren zur herstellung von linezolid und verwandten verbindungen
CA2569404A1 (en) 2004-06-04 2005-12-22 Amphora Discovery Corporation Quinoline- and isoquinoline-based compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof
WO2005123672A2 (en) 2004-06-14 2005-12-29 Takeda San Diego, Inc. Kinase inhibitors
EP1781653A1 (en) 2004-07-05 2007-05-09 Astex Therapeutics Limited 3,4-disubstituted pyrazoles as cyclin dependent kinases (cdk) or aurora kinase or glycogen synthase 3 (gsk-3) inhibitors
WO2006008754A1 (en) 2004-07-20 2006-01-26 Symed Labs Limited Novel intermediates for linezolid and related compounds
WO2006039164A2 (en) 2004-09-29 2006-04-13 Amr Technology, Inc. Novel cyclosporin analogues and their pharmaceutical uses
WO2006091737A1 (en) 2005-02-24 2006-08-31 Kemia, Inc. Modulators of gsk-3 activity
TW200716636A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
CN101341138B (zh) 2005-06-30 2012-11-14 詹森药业有限公司 作为gsk-3抑制剂的环状苯胺基-吡啶并三嗪类
EP1749523A1 (en) 2005-07-29 2007-02-07 Neuropharma, S.A. GSK-3 inhibitors
US7514068B2 (en) 2005-09-14 2009-04-07 Concert Pharmaceuticals Inc. Biphenyl-pyrazolecarboxamide compounds
UY29825A1 (es) 2005-10-03 2007-05-31 Astrazeneca Ab Derivados sustituidos de 3h-imidazol-(4,5 b (beta))piridina-2-il benzoatos y benzamidas, composiciones farmacéuticas que los contienen y aplicaciones
CA2637392A1 (en) 2006-01-23 2007-07-26 Crystalgenomics, Inc. Imidazopyridine derivatives inhibiting protein kinase activity, method for the preparation thereof and pharmaceutical composition containing same
US20090221576A1 (en) 2006-02-02 2009-09-03 Astrazeneca Ab Global Intellectual Property Pharmaceutical Use of 2-Hydroxy-3-[5-(Morpholin-4-Ylmethyl) Pyridin-2-YL]-1H-IN-Dole-5-Carbonitrile as a Free Base or Salts
WO2007120102A1 (en) 2006-04-19 2007-10-25 Astrazeneca Ab New substituted oxindole derivatives
EP1849785A1 (en) 2006-04-28 2007-10-31 Neuropharma, S.A. N-(2-Thiazolyl)-amide derivatives as GSK-3 inhibitors
US7622495B2 (en) 2006-10-03 2009-11-24 Neurim Pharmaceuticals (1991) Ltd. Substituted aryl-indole compounds and their kynurenine/kynuramine-like metabolites as therapeutic agents
US8642598B2 (en) * 2006-10-21 2014-02-04 Abbvie Inc. Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors
US8796267B2 (en) 2006-10-23 2014-08-05 Concert Pharmaceuticals, Inc. Oxazolidinone derivatives and methods of use
NZ577768A (en) 2006-12-19 2012-01-12 Vertex Pharma Aminopyrimidines useful as inhibitors of protein kinases
ES2446269T3 (es) 2006-12-19 2014-03-06 The Board Of Trustees Of The University Of Illinois 3-Benzofuranil-4-indolil-maleimidas como potentes inhibidores de GSK-3 para trastornos neurodegenerativos
KR101335845B1 (ko) 2007-02-15 2013-12-02 에프. 호프만-라 로슈 아게 Ｔａａｒ1 리간드로서의 2-아미노옥사졸린
RU2009138136A (ru) 2007-04-18 2011-05-27 Астразенека Аб (Se) Новый способ получения соединения 2-гидрокси-3-[5-(морфолин-4-илметил)пиридин-2-ил]1н-индол-5-карбонитрила 701
US7528131B2 (en) 2007-04-19 2009-05-05 Concert Pharmaceuticals Inc. Substituted morpholinyl compounds
EP1992624A1 (en) 2007-05-16 2008-11-19 Sanofi-Aventis Heteroarylamide pyrimidone compounds
US7531685B2 (en) 2007-06-01 2009-05-12 Protia, Llc Deuterium-enriched oxybutynin
BRPI0811065A2 (pt) * 2007-06-08 2014-12-02 Abbott Lab Indazóis 5-heteroaril substituídos como inibidores de quinase
WO2009035598A1 (en) 2007-09-10 2009-03-19 Concert Pharmaceuticals, Inc. Deuterated pirfenidone
US20090118238A1 (en) 2007-09-17 2009-05-07 Protia, Llc Deuterium-enriched alendronate
US20090088416A1 (en) 2007-09-26 2009-04-02 Protia, Llc Deuterium-enriched lapaquistat
US20090082471A1 (en) 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched fingolimod
WO2009045476A1 (en) 2007-10-02 2009-04-09 Concert Pharmaceuticals, Inc. Pyrimidinedione derivatives
US20090105338A1 (en) 2007-10-18 2009-04-23 Protia, Llc Deuterium-enriched gabexate mesylate
US8410124B2 (en) 2007-10-18 2013-04-02 Concert Pharmaceuticals Inc. Deuterated etravirine
WO2009055006A1 (en) 2007-10-26 2009-04-30 Concert Pharmaceuticals, Inc. Deuterated darunavir
CA2720659C (en) * 2008-04-24 2016-10-18 Abbott Gmbh & Co. Kg 1-(7-(hexahydropyrrolo[3,4-c]pyrrol-2(1h)-yl)quinolin-4-yl)-3-(pyrazin-2-yl)urea derivatives and related compounds as glycogen synthase kinase 3 (gsk-3)
TW201040191A (en) 2009-03-27 2010-11-16 Abbott Gmbh & Co Kg Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
US9090592B2 (en) * 2010-12-30 2015-07-28 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors

Also Published As

Publication number Publication date
SG191789A1 (en) 2013-08-30
SG10201406098UA (en) 2014-11-27
WO2012089828A2 (en) 2012-07-05
BR112013016928A2 (pt) 2020-10-27
JP2017122089A (ja) 2017-07-13
CA2821863A1 (en) 2012-07-05
US20120172376A1 (en) 2012-07-05
RU2013135477A (ru) 2015-02-10
JP2014501269A (ja) 2014-01-20
CN103476766B (zh) 2016-08-10
MX2013007702A (es) 2013-11-20
WO2012089828A3 (en) 2012-09-20
ZA201304756B (en) 2016-07-27
CN103476766A (zh) 2013-12-25
US9540370B2 (en) 2017-01-10
RU2623427C2 (ru) 2017-06-26
EP2658854B1 (en) 2017-12-13
KR20140003518A (ko) 2014-01-09
US20150274724A1 (en) 2015-10-01
JP6144201B2 (ja) 2017-06-07
AU2011351375B2 (en) 2016-08-04
AU2011351375A1 (en) 2013-06-20
NZ611314A (en) 2015-06-26
EP3351543A1 (en) 2018-07-25
IL226676A (en) 2015-08-31
EP2658854A2 (en) 2013-11-06
KR101860297B1 (ko) 2018-05-23
US9090592B2 (en) 2015-07-28

Similar Documents

Publication Publication Date Title
MX2013007702A (es) Compuestos heterociclicos y su uso como inhibidores de la cinasa 3 de glucogeno sintasa.
MX336726B (es) Compuestos heterociclicos y su uso como inhibidores de la glucogeno sintasa quinasa-3.
MX2012013197A (es) Inhibidores de indazol de cinasa.
MX2010009207A (es) Compuestos y composiciones heterociclicos como inhibidores de c-kit y pdgfr cinasa.
MX2013001361A (es) 4-(1h-indol-3-il) - pirimidina como inhibidores de alk.
MD4800C1 (ro) Compuşi de aminopirimidinil ca inhibitori de JAK
MD20140109A2 (ro) Compuşi ai indolului şi indazolului care activează AMPK
MX2012001070A (es) Derivados de oxazina y su uso como inhibidores de bace para el tratamiento de trastornos neurologicos.
TN2012000249A1 (en) Pyrazine derivatives and their use in the treatment of neurological disorders
TN2014000016A1 (en) 4 - piperidinyl compounds for use as tankyrase inhibitors
EP2571876A4 (en) SUBSTITUTED SEVEN-HETEROCYCLIC COMPOUNDS AS DIPEPTIDYL-PEPTIDASE IV INHIBITORS FOR THE TREATMENT OF DIABETES
GEP20135785B (en) Pyrrolopyrimidine compounds as cdk inhibitors
MX2012015252A (es) Estimuladores de sgc.
PH12014502056A1 (en) 3,5-diaminopyrazole kinase inhibitors
MX2013008296A (es) Diarilacetileno hidracido que contiene inhibidores de tirosina quinasa.
MY167898A (en) Co-crystals and salts of ccr3-inhibitors
MX2013004004A (es) Pirrolidinonas como inhibidores de metionina aminopeptidasa (metap-2).
MY184858A (en) Substituted pyridopyrimidine compounds and their use as flt3 inhibitors
MX2020009397A (es) Composiciones y metodos para inhibicion de la via jak.
WO2009156041A3 (de) Thiazolyl-piperidinderivate
MX2009004140A (es) Compuestos heterociclicos y su uso como inhibidores de la glucogeno sintasa quinasa 3.
WO2009094560A3 (en) Thienopyranones as kinase inhibitors
MX2012000177A (es) 2-carboxamida-cicloamino-ureas sustituidas.
MX2013002208A (es) Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes.
MY148732A (en) Triazolium salts as par1 inhibitors, production thereof, and use as medicaments